Blood Test Detects Cancers Before Symptoms

A healthcare professional in a lab preparing vaccine vials

A single blood draw could soon detect over 50 cancers before symptoms strike, potentially slashing deaths from the deadliest types by years.

Story Highlights

GRAIL’s Galleri test shows 74% sensitivity for 12 deadliest cancers, 40% overall, with just 0.4% false positives.
70% of U.S. cancer deaths stem from types without standard screening; MCED tests target this gap.
Pathfinder II study of 36,000 adults found 53% of cancers at stage I or II, when survival odds soar.
GRAIL plans FDA approval in late 2026; current $950 cost limits access to cash-paying patients.
Combining with existing screens boosts detection seven-fold, per GRAIL president.

GRAIL Launches Galleri in 2021

GRAIL released Galleri, the first multi-cancer early detection test, in 2021. The Menlo Park company analyzes cell-free DNA from a blood sample to spot signals from over 50 cancers. Tumors shed unique methylation patterns into the bloodstream, which advanced sequencing detects. Since launch, Galleri performed over 370,000 tests. This breakthrough targets pancreatic, liver, ovarian, and esophageal cancers lacking routine screens. Early adoption focused on high-risk adults over 50.

Pathfinder II Delivers Breakthrough Data

GRAIL published Pathfinder II results in December 2025 from 36,000 U.S. and Canadian adults. The study achieved 74% sensitivity for 12 lethal cancers including pancreas, liver, ovary, esophagus, and stomach. Overall sensitivity hit 40% across all detected cancers. False positives registered at 0.4%, the lowest rate among MCED tests. Crucially, 53% of findings occurred at stage I or II, and 70% at stages I-III, when cures remain viable. These numbers promise real survival gains.

Test Accuracy Pinpoints Cancer Origins

Galleri provides cancer signal origin with over 90% accuracy, guiding doctors to precise follow-up scans or biopsies. Patients receive directional information, not definitive diagnoses, prompting targeted imaging like CT or PET. This precision avoids broad, invasive hunts. Experts like Dr. Nima Nabavizadeh of Oregon Health & Science University call it a potential overhaul of screening, catching cancers earliest when treatment succeeds most. Combined with mammograms or colonoscopies, detection multiplies seven-fold.

Competitors Challenge GRAIL’s Lead

Exact Sciences developed Cancerguard, another MCED test seeking FDA approval. GRAIL holds first-mover status, but competition spurs innovation and price drops. Both leverage cfDNA tech born from decade-old liquid biopsy advances. The FDA demands rigorous safety and efficacy proof before greenlighting as medical devices. American Cancer Society praises promise but urges more studies on broad versus high-risk use. Insurance payers scrutinize cost-benefit before coverage.

Access Barriers and Future Promise

Galleri costs $950 out-of-pocket with physician prescription; most insurers deny coverage now. Affluent patients dominate early users, raising equity issues for underserved groups. FDA submission targets late 2026, potentially unlocking reimbursement and standard care for 50+ adults. Long-term, earlier detection of aggressive cancers could cut mortality and healthcare costs via cheaper stage I treatments. Protocols for results and follow-ups challenge providers, but benefits align with personal responsibility in health.